• 114: Phase 3 PHOENIX Study, AMX0035, and Amylyx's Future Drug Development

  • May 3 2024
  • Duración: 20 m
  • Podcast

114: Phase 3 PHOENIX Study, AMX0035, and Amylyx's Future Drug Development

Escúchala gratis

Ver detalles del espectáculo

  • Resumen

  • Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.


    In this episode, Justin Klee and Josh Cohen, cofounders and cochief executive officers of Amylyx Pharmaceuticals, sat down at the recently concluded AAN Annual Meeting to discuss the results from the pivotal phase 3 PHOENIX trial (NCT) of AMX0035 (Relyvrio) in patients with amyotrophic lateral sclerosis (ALS). The duo provided clarity on the findings, positive takeaways from the disappointing data, and the lessons learned in ALS drug development. In addition, the two provided commentary on the future plans of the therapy in other tauopathies like progressive supranuclear palsy and neurologic conditions like Wolfram syndrome. Furthermore, Klee and Cohen shared thoughts on the company's drug pipeline, including AMX0114, an antisense oligonucleotide in development for patients with ALS.

    Looking for more neuromuscular discussion? Check out the NeurologyLive® Neuromuscular clinical focus page.

    Episode Breakdown:
    • 1:05 – Decision behind removing AMX0035 from market
    • 3:00 – Lessons from PHOENIX, AMX0035 drug development program
    • 6:45 – Unraveling PHOENIX study data
    • 10:00 – Neurology News Minute
    • 12:10 – Potential of AMX0035 in other tauopathies, neurologic conditions
    • 15:00 – Outlook of antisense oligonucleotide AMX0114 in ALS

    The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

    • Diazepam Buccal Film’s Role in Treating Intermittent Pediatric Seizures, with Michael Rogawski, MD, PhD
    • Ocrelizumab Gains EU CHMP Positive Opinion for Subcutaneous Formulation to Treat MS
    • FDA Approves Sprinkle Formulation of Neurocrine Biosciences’ Valbenazine for Tardive Dyskinesia or Huntington disease Chorea

    Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.
    Más Menos
activate_WEBCRO358_DT_T2
Enfermedades Físicas Hygiene & Healthy Living Ciencia
Más Menos

Lo que los oyentes dicen sobre 114: Phase 3 PHOENIX Study, AMX0035, and Amylyx's Future Drug Development

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.

Reseñas de Audible.com

Opiniones de Amazon
No hay comentarios disponibles